Prostate Cancer Immunotherapy

Anogen supports your research in prostate cancer immunotherapy

prostate cancer immunotherapy

 Current and emerging trends in prostate cancer immunotherapy

Adam Schatz, Badar M Mian

Asian Journal of Andrology (2019) 21, 6–11; doi: 10.4103/aja.aja_52_17; published online: 24 November 2017

Anogen provides highly specific, sensitive and consistent antibody-based products supporting your research in prostate cancer immunotherapy.


Matched Antibody Pair

Elisa kits

mAb anti-Human PSMA

mAb anti-Human GM-CSF

mAb anti-Human PSA

mAb anti-Human PD-1

mAb anti Human PD-L1

Rat anti-Mouse CD4

Rat anti-Mouse CD8

Human GM-CSF Matched Pair

mAb anti-Human PD-1 Matched Pair

mAb anti Human PD-L1 Matched Pair




Human GM-CSF ELISpot Kit



Human Free PSA ELISA Kit

Human PD-1 ELISA Kit

Human PD-L1 ELISA Kit

Prostate cancer incidence and treatments

Prostate cancer is the second most common cancer in men. One in seven Canadian men will be diagnosed with prostate cancer in their lifetime. There were 1.3 million new cases in 2018 worldwide.

The most common treatments for prostate cancer are radical prostatectomy, hormone therapy, chemotherapy, and radiation. Researches showed that combinational treatment strategies are needed to improve the survival of patients with advanced prostate cancer and mCRPC. Since the first immunotherapy for prostate cancer, Sipuleucel-T, was approved by FDA in 2010, there has been emerging interest in utilizing immunotherapy in prostate cancer.

Immunotherapy targets

Prostate cancer has slow growth kinetics, which reduces the effectiveness of traditional chemotherapies but may increase the effectiveness of immunomodulatory approaches. The immune environment changes over time as the disease status evolves and in response to treatment. Prostate cancer microenvironment is in general an immunosuppressive condition.

The prostate has multiple tumorspecific antigens, such as prostate-specific antigen (PSA), prostate acid phosphatase (PAP), prostate stem cell antigen (PSCA), and prostatespecific membrane antigen (PSMA), among others, providing antigenic targets for the design of immune therapy.

Checkpoint inhibitors that target either cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) or the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have also shown potential in prostate cancer therapy.

Immunotherapy on the market and in clinical researches

There are two primary immune targeting approaches intended to exploit the natural immune system against cancer cells:

(1) antigentargeted immunotherapy, i.e. vaccines: PROVENGE® (Sipuleucel-T) selectively targets the prostate-specific antigen (PSA). Ex vivo culture with PAP-GM-CSF, APCs from patient take up and process recombinant target antigen into small peptides then are displayed on the APC surface. Antigen-loaded APCs are then infused back into the patient to activate the immune system to attack prostate cancer.

(2) immunomodulatory immunotherapy, i.e. immune checkpoint inhibitors and Tcell regulatory drugs (CTLA4 inhibitors, PD1, PDL1 inhibitors): 

Several new PD1 (nivolumab, pembrolizumab) and PDL1 inhibitors (atezolizumab) are under investigation for clinical effectiveness in advanced prostate cancer.

New research trend in prostate cancer immunotherapy

Immunotherapy combined with other treatment modalities are being considered in a number of trials, in both hormonesensitive and castrationresistant prostate cancer. These combinations include immune checkpoint inhibitors with vaccines, chemotherapy, radiation therapy, focal ablation treatments, surgery, and ADT.